Workday Delivers Its First Data-as-a-Service Offering With Workday Benchmarking
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/9/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Atlassian results seen as 'game changer' for AI kills software worries
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
FBN Securities Upgrades Workday (WDAY) to Outperform
October 11, 2017 12:45 PM EDTFBN Securities upgraded Workday (NASDAQ: WDAY) from Sector Perform to Outperform with a price target of $125.00 (from $115.00).
Analyst Shebly Seyrafi notes subscription revenue backlog growth was also disclosed to be 44% Y/Y last quarter (to ~$4.4B from ~$3.1B the year before),... More
Cowen Remains Sidelined on Workday (WDAY) Following Analyst Day
October 11, 2017 7:26 AM EDTCowen reiterated a Market Perform rating and $100.00 price target on Workday (NASDAQ: WDAY) following the company's analyst day. The analyst meeting focused on discussing business momentum across existing product segments as well as new product focus including PaaS and Analytics.
Overall, based on... More
